A pharmacoeconomic appraisal of therapies for hepatitis B and C

Expert Opinion on Pharmacotherapy
Zobair M YounossiK M Shermock

Abstract

In the recent years, advances in the treatment of chronic hepatitis B and C have shown that newer, more expensive therapy may result in higher sustained viral response rates. In light of this, the pertinent question for healthcare decision-makers centres around whether this increase in efficacy 'justifies' the additional cost. Pharmacoeconomics is dedicated to helping answer these types of questions. In this article, we will discuss the clinical aspects of hepatitis B and C, recent advances in treatment and studies of the cost-effectiveness of these treatments.

References

Mar 31, 1977·The New England Journal of Medicine·M C Weinstein, W B Stason
May 1, 1988·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Y F LiawT J Chen
Feb 1, 1995·Seminars in Liver Disease·Z D Goodman, K G Ishak
Sep 26, 1997·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M J TongJ Lubina
Sep 26, 1997·Hepatology : Official Journal of the American Association for the Study of Liver Diseases
Jul 4, 1998·Lancet·A M Di Bisceglie
Jan 6, 1999·JAMA : the Journal of the American Medical Association·J B WongS G Pauker
Aug 19, 1999·The New England Journal of Medicine·M J AlterH S Margolis
Oct 26, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Z M YounossiK M Shermock
Mar 24, 2000·Journal of Clinical Gastroenterology·S A Sarbah, Z M Younossi
Apr 12, 2000·The American Journal of Medicine·J B WongS G Pauker

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.